The London School of Hygiene and Tropical Medicine: a new century of malaria research. by Riley, EM
Riley, EM (2000) The London School of Hygiene and Tropical Medicine:
a new century of malaria research. Memrias do Instituto Oswaldo
Cruz, 95 (Supp1).pp.25−32.ISSN0074−0276DOI : https : //doi.org/10.1590/S0074−
02762000000700004
Downloadedfrom : http : //researchonline.lshtm.ac.uk/20149/
DOI : 10.1590/S0074− 02762000000700004
25Mem Inst Oswaldo Cruz, Rio de Janeiro, Vol. 95, Suppl. I: 25-32, 2000
The London School of Hygiene and Tropical Medicine:
a New Century of Malaria Research
Eleanor M Riley
Department of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, Keppel St.,
London WC1E 7HT, UK
The global malaria situation has scarcely improved in the last 100  years, despite major advances
in our knowledge of the basic biology, epidemiology and clinical basis of the disease. Effective malaria
control, leading to a significant decrease in the morbidity and mortality attributable to malaria, will
require a multidisciplinary approach. New tools – drugs, vaccine and insecticides – are needed but
there is also much to be gained by better use of existing tools: using drugs in combination in order to
slow the development of drug resistance; targeting resources to areas of greatest need; using geographic
information systems to map the populations at risk and more sophisticated marketing techniques to
distribute bed nets and insecticides. Sustainable malaria control may require the deployment of a
highly effective vaccine, but there is much that can be done in the meantime to reduce the burden of
disease.
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The London School of Hygiene and Tropical
Medicine was established in 1899, almost
simultaneously with the School of Tropical
Medicine in Liverpool and with the Instituto
Oswaldo Cruz, during the renaissance of research
on infectious and tropical diseases that followed
the pioneering work of Koch, Pasteur, Manson,
Ross, Cruz, and Chagas, among others. Work on
malaria has been central to the London School since
its inception. Patrick Manson was the first
Professor of Tropical Medicine; he initiated and
supported the work of Ronald Ross in India that
led to the discovery of mosquito transmission of
malaria and he was followed by distinguished
malariologists such as Garnham, Macdonald and
Bruce-Chwatt who established long-lasting
collaborative research and control programmes in
many malaria-endemic countries. The commitment
to malaria research continues to this day, with six
professorial staff, 40 other academic staff and 30
PhD students working on malaria, in 30 different
endemic countries. The main strength of the School
lies in the interdisciplinary nature of our work, with
expertise from molecular genetics to health policy
and economics of malaria control.
Malaria remains as big a threat to human health,
welfare and economic development as ever. Despite
decades of research, and major steps forward in
treatment and prevention, the death toll remains
above a million per year with more than 500 million
clinical cases annually. The way forward must be a
multidisciplinary approach to malaria control,
comprising development and deployment of new
anti-malarial drugs and drug combinations,
prevention of human-vector contact by use of
insecticide-treated materials, improved diagnosis
and case management, monitoring of malaria
outbreaks and epidemic prediction, development
of a sustainable infrastructure for policy making
and implementation at the local level and –
importantly – health education. The development
of a malaria vaccine must be seen as a vital
contribution to this overall strategy but not as a
panacea.
THE LONDON SCHOOL OF HYGIENE AND
TROPICAL MEDICINE (LSHTM)
LSHTM is a financially independent
postgraduate medical school within The University
of London. The School has three complementary
roles: (i) to train future academics, researchers,
policy-makers and practitioners in all aspects of
public health and tropical medicine; (ii) to conduct
high quality research; and (iii) to provide
consultancy services. Our aim, through teaching,
research and consultancy, is to contribute to the
development of new tools for improving health, to
disseminate this information and to influence policy
in order to improve health, worldwide.
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Teaching is offered at several levels, all post-
graduate. Taught courses include masters degrees
(MSc) – full or part-time at LSHTM or by distance
learning – and short courses (typically one week to
three months duration) including for example short
courses in epidemiology and statistics, tropical
nursing, the Diploma in Tropical Medicine and
Hygiene and refresher courses in infectious dis-
eases. Research degrees include PhD, DrPH, MPhil
and MRes (Master of Science by Research). In the
1999-2000 academic year there were 512 students
from 82 different countries studying on 20 different
masters courses at LSHTM and 257 students from
70 countries registered for research degrees.
The costs of studying full time in London are
rising all the time and are beyond the reach of many
students from overseas. This is borne out for ex-
ample by the number of Brazilian students currently
registered at LSHTM, which has fallen from 28 in
1992 to 7 in the academic year 1999-2000. In order
to fulfill our mission of making our courses avail-
able to everyone who could benefit from them, we
have developed two new initiatives to reach out to
overseas students. The first of these is the Dis-
tance Learning Programme, which currently offers
diploma and masters level training in three areas -
Health Systems Management, Infectious Diseases
and Epidemiology; there are currently over 800 stu-
dents from 44 countries registered on these courses.
The second initiative is the ‘split’ PhD where over-
seas students can spend time in their home institu-
tion pursuing their research project; out of their 3-
year study time, students are required to spend
only nine months in London. More details of the
LSHTM teaching programme can be found at
www.lshtm.ac.uk/prospectus.
Our research falls into two main categories – clini-
cal/laboratory research and community based re-
search. In the last UK research assessment exercise,
which grades all research in UK universities, the
School’s research was awarded maximum scores in
both of these areas. This rates our research as “in-
ternationally excellent” and places the School in the
top 5 of the 40 UK medical schools. Our current re-
search income is approximately £17m per year. The
areas of research covered within the School’s three
departments are shown in Table I. In order to
capitalise on our multidisciplinary skills, cross-
departmental research centres have been
established, which cut across traditional subject
areas and disciplines, to bring together a critical mass
of people to work on complex problems. Examples of
current research centres are shown in the Table II.
MALARIA RESEARCH IN THE 21st CENTURY
Malaria remains, along with tuberculosis and
human immunodeficiency virus/acquired immuno-
deficiency syndrome, one of the three most impor-
tant infectious diseases worldwide. The number of
deaths is extremely difficult to estimate as many
malaria deaths take place in the community without
the patient ever coming into contact with the for-
mal health care system, but recent estimates indi-
cate approximately one million deaths in Africa each
year, excluding deaths associated with malaria in
pregnancy (Snow et al. 1999). Despite heroic ef-
forts to control, eliminate and eradicate malaria in
the middle years of the 20th century and despite
some substantial advances in the last few years in
developing new drugs (White et al. 1999) and new
means to interrupt human-vector contact (Lengeler
et al. 1998), the number of people infected with, and
dying from malaria has scarcely changed. This is
due in large part to the failure of these new tools to
be applied in the areas where they can be of most
benefit; getting research into practice has been an
under-rated and under-resourced aspect of the re-
search agenda. Nevertheless, it has become clear
that only a sustained, multi-pronged approach to
malaria control will have any significant impact on
the disease. This realization is implicit in the ap-
proach of the 21st century programme to reduce
the burden of disease caused by malaria, the Roll
Back Malaria programme of the World Health Or-
ganization, which endeavours to use whatever com-
bination of available tools is best suited to control-
ling malaria in a specific location rather than rely-
ing on one or two tools and applying them every-
where (Nabarro & Tayler 1998, Nabarro 1999).
TABLE I
Research Units at the London School of Hygiene and Tropical Medicine
Department of  Epidemiology and Department of Public Health Department of Infectious and  Tropical
Population Health and Policy Diseases
Cancer and Public Health Environmental Epidemiology Immunology
Centre for Population Studies Health Policy Infectious Disease Epidemiology
Epidemiology Health Promotion Research Pathogen Molecular Biology and Biochemistry
Maternal and Child Epidemiology Health Services Research Disease Control and Vector Biology
Medical Statistics Clinical Sciences
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Whilst funders and policy makers must take
some of the blame for the slow uptake of new
research findings, researchers themselves must
share the responsibility. Research must be aimed,
ultimately, at delivering tools that are appropriate
and affordable. This requires extensive and
frequent dialogue between basic researchers and
those working at the more applied end of the
spectrum to make sure that research priorities
continue to meet the needs of the malaria control
community. Several new initiatives – Roll Back
Malaria, the Multilateral Initiative on Malaria, the
Medicines for Malaria Venture, the Malaria Vaccine
Initiative – have all recently taken this on board
and are promoting truly integrated, multidisciplinary
approaches to research (Alonso & Dgedge 1999).
MALARIA RESEARCH AT LSHTM
LSHTM is well placed to take advantage of this
multidisciplinary – and inter-disciplinary –
atmosphere as malaria research within the School
is about as broad-based as it is possible to be. In
addition to basic research programmes in population
genetics, molecular biology, biochemistry, im-
munology and cell biology, the School also hosts
two major programmes funded by the UK
Department for International Development (DfID)
– the Malaria Consortium which, jointly with the
Liverpool School of Tropical Medicine, provides
consultancy services for malaria control, and a
programme of applied and operational research in
malarious countries of Africa and Asia, with special
emphasis on the evaluation, development and
implementation of insecticide-treated mosquito
nets; prediction and prevention  of malaria
epidemics associated with climatic variation; trials
of new drugs and candidate vaccines, and the
epidemiology of urban malaria. Our research income
has just received a significant boost from a major
investment from the UK Medical Research Council
for a programme of work on the relationship be-
tween malaria transmission intensity and disease
burden (in collaboration with the National Institute
for Medical Research and the Kilimanjaro Christian
Medical Centre in Tanzania) and a five year
programme from the Bill and Melinda Gates
Foundation for a multinational programme on the
treatment and prevention of malaria.
In order to facilitate interactions between such
a disparate group of researchers, the LSHTM
Malaria Centre was established in 1998, under the
leadership of Professor Brian Greenwood and
myself. The Centre currently comprises approxi-
mately 50 academic staff and 30 PhD students. The
aims of the Centre are to facilitate malaria research,
to develop links between scientists from different
disciplines, to facilitate links between the School
and colleagues in malaria endemic areas, to offer
training in malaria research and control and thereby
to contribute to global efforts to control malaria.
Details of current areas of research within the Ma-
laria Centre, and the principal investigators for each
of these areas, are available at http://
www.lshtm.ac.uk/centres/malaria.
In order to give some idea of the breadth of
malaria activities at LSHTM, I have selected six areas
of research to present in more detail.
POPULATION GENETICS OF THE PARASITE AND
ITS VECTORS
Malaria parasites, mosquito vectors and human
hosts are all genetically diverse; interactions among
these three populations are affected by the prevail-
ing genotypes of each population. The most obvi-
ous manifestations of parasite polymorphisms are
anti-malarial drug resistance and antigenic diversity.
The role of allelic variation in genes encoding
immunodominant antigens of the parasite is hotly
debated but it seems clear that antigenic polymor-
phism can lead to immune evasion. The data are most
convincing for evasion of cell-mediated immunity -
polymorphisms cluster around immunodominant T
cell epitopes (Good et al. 1988), single amino acid
substitutions in T cell epitopes lead to loss of T cell
recognition (Zevering et al. 1994) or antagonism of T
cell responses (Plebanski et al. 1999) and
nonsynonymous mutations out-number synony-
mous mutations within T cell epitopes (Hughes et al.
1995). Polymorphisms that allow the parasite to evade
host immune responses will tend to be maintained
by frequency dependent (or balancing) selection –
i.e. the allele will be favoured when it is rare, because
very few people will have developed a specific im-
mune response to the protein encoded by it, and the
frequency of the allele will increase. When a suffi-
ciently large proportion of the population have been
infected with this parasite genotype and become
immune to it, the allele will be selected against and
its frequency will fall.
TABLE II
Cross-departmental Research Centres
European Centre on Health of Societies in Transition
European Observatory on Health Care Systems
Water and Environmental Health at London and
Loughborough
Malaria Centre
Collaborative Centre for Economics of Infectious
Disease
Centre for Ageing and Public Health
Centre on Globalisation, Environmental Change and
Health
Centre on Alcohol and Health
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Allele frequency distributions can be used to
detect balancing selection (Conway 1997). Using
this approach, David Conway and colleagues have
identified a polymorphic region near the 5’ end of
the merozoite surface protein 1 (MSP1) gene of
Plasmodium falciparum that appears to be under
balancing selection and has gone on to show that
naturally acquired IgG antibodies to this N terminal
region of the MSP1 protein are strongly associated
with resistance to clinical malaria in a malaria
exposed population (Conway et al. 2000). This has
interesting implications for the development of
MSP1 vaccines as it has previously been thought
that protective antibodies specifically target the C
terminus of MSP1 (Egan et al. 1995, Guevara Patino
et al. 1997).
David Conway’s group has also used a
population genetic approach to obtain more reliable
estimates of the historical spread of P. falciparum.
Using polymorphisms within the mitochondrial DNA
(mtDNA) sequence they have demonstrated that
global populations of  P. falciparum emerged from
an ancestral population within the last 50,000 years.
This population diverged within Africa, with one
version of the mtDNA sequence being carried to the
east to give rise to P. falciparum populations in
Southeast Asia and another version of the sequence
moving west in Africa and eventually being carried
to South America (Conway et al. unpub. data).
Studies of this kind have important implications for
understanding the spread of other parasite traits, for
example drug resistance, and for unraveling both
historical and current interactions between host and
parasite in genetically diverse populations.
Mosquito populations are also amenable to
population mapping using genetic markers. In some
areas of low, and particularly seasonal, malaria
transmission, larviciding is used as a method of
malaria control. During the dry season, mosquitoes
survive in a relatively small number of refugia –
typically permanent water bodies – and are thus
vulnerable to elimination by larvicidal chemical
sprays. The success of this approach depends
upon how quickly the area is repopulated during
the following wet season by mosquitoes originat-
ing outside the control area. Cally Roper has been
using microsatellite markers of Anopheles gambiae
sl to characterize mosquito populations in different
areas of KwaZulu-Natal in South Africa. Signifi-
cant differences in the allele frequencies at differ-
ent microsatellite loci have been found in different
parts of the region, indicating that mosquito popu-
lations are subdivided and sub-populations are iso-
lated from each other. The implication of this find-
ing is that migration of mosquitoes within the re-
gion is limited and dry season larviciding may there-
fore be an effective means of vector control.
ANTI-MALARIAL DRUGS AND MALARIA TRANS-
MISSION
Most anti-malarial drugs act against the asexual,
intra-erythrocytic stages of the parasite, having
little or no effect on sporozoites, liver stages or
gametocytes. The artemisinin group of anti-malarial
drugs, derived from the Chinese herbal remedy
qinghao or sweet wormwood, has however been
reported to have gametocytocidal effects (Kumar
& Zheng 1990) and may thus, if widely used, either
alone or in combination with other antimalarials,
have an impact on malaria transmission (Price et al.
1996). In The Gambia, Lorenz von Seidlein, a PhD
student at LSHTM, has compared the efficacy of a
combination of the artemisinin derivative artesunate
with sulphadoxine/pyrimethamine (SP) with SP
alone and has shown that the combination is safe
and highly efficacious (von Seidlein et al. 2000). A
follow-up study aims to see whether mass
chemotherapy at the start of the malaria season
can delay or prevent the annual increase in malaria
cases by removing the source of infection for newly
emerged mosquitoes.
Geoff Targett, Chris Drakely and Colin
Sutherland have directly addressed the question
of whether certain combinations of anti-malarial
drugs can interfere with transmission of malaria to
mosquitoes. They have compared the effect of four
different drug combinations on the prevalence of
gametocytes in the four weeks following treatment
and have shown that treatment with SP is
associated with up to three-fold higher prevalence
of gametocytes post treatment compared to
treatment with chloroquine (von Seidlein et al. 2000,
Targett et al., unpub. data). This indicates that
changing the first line drug from chloroquine to SP
in endemic countries could be associated with an
increase in the infectious reservoir and possibly
higher levels of transmission. If these gametocytes
arise from drug resistant clones of malaria, the
spread of drug resistance may also be facilitated;
this issue is currently being addressed at LSHTM.
Importantly, this study showed that the combination
of SP with artesunate reduced the prevalence of
gametocytaemia to levels below those seen with
chloroquine. However, membrane-feeding
experiments showed that the few gametocytes that
were present in people treated with artesunate/SP
remained infective for mosquitoes. These studies
suggest that artemisinin derivatives in some way
reduce the levels of circulating gametocytes but
are not in fact completely gametocytocidal.
Meanwhile, novel anti-malarial drugs that spe-
cifically target gametocyte development or
gametocyte survival would be of enormous benefit
– particularly in areas of marginal or highly sea-
sonal malaria transmission, where their transmis-
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sion reducing potential would be most obvious.
David Baker is taking a fundamental approach to
this problem, using data from the P. falciparum
genome project (http://www.sanger.ac.uk/Projects/
P_falciparum) to identify genes that are specifically
expressed during development of the sexual (ga-
metocyte) stage of the life cycle in order to identify
novel metabolic pathways that may be amenable to
pharmacological manipulation (Muhia D et al. 2000).
Once candidate genes have been identified, genetic
transformation of malaria parasites in vitro offers a
stringent method for drug target validation.
MECHANISMS OF IMMUNITY TO MALARIA
Rational design of malaria vaccines requires that
we identify the targets of protective immune
responses and that we determine which immune
effector mechanisms actually contribute to parasite
killing and resistance to clinical disease. Population
genetic approaches can help to identify potential
protective antigens (see above) but more direct ap-
proaches, such as immunoepidemiological studies
of the association between a specific immune re-
sponse to a particular antigen and susceptibility or
resistance to clinical malaria, can also be used (Riley
et al. 1991, Al-Yaman et al. 1994, Taylor et al. 1998).
We have recently completed an immunoepidemio-
logical study designed to test whether anti-malarial
antibodies transferred from mother to child across
the placenta, can in fact protect neonates and in-
fants from malaria infection or malaria disease. In-
fants, under the age of 4-6 months, are well known
to be relatively resistant to clinical malaria but the
mechanism of resistance may be either immuno-
logical or physiological (Brabin 1990). In a prospec-
tive, longitudinal study of a birth cohort of infants
in southern Ghana, we were unable to find any as-
sociation between levels, antigenic specificity or
antibody isotype/subclass of maternal antibody and
resistance of the infants to malaria infection (Riley
et al. 2000). However, the overwhelming majority of
malaria infections in children under six months of
age were asymptomatic and of very low density
(Wagner et al. 1998); infants clearly possess mecha-
nisms for preventing parasite replication and these
may well be independent of maternally acquired
antibody.
An alternative explanation for the lack of clini-
cal symptoms of malaria in infants, especially in
children who developed significant levels of
parasitaemia, may be that the typical febrile re-
sponse to infection – which is mediated by inflam-
matory cytokines such as TNFα – is at least par-
tially immune-mediated and dependent upon am-
plification by the acquired (T cell-mediated) immune
response (Riley 1999). If so, then primary malaria
infections in infants may be silent infections – which
may remain undiagnosed and untreated – and may
predispose to chronic infection and the eventual
development of anaemia. Conversely, chronic low-
grade parasitaemia may be a prerequisite for devel-
opment of anti-malarial immunity (premunition).
Clearly, a better understanding of the natural his-
tory of malaria infections in small children may have
implications for our understanding of acquired im-
munity but also for appropriate management of low
grade infections in infants.
MALARIA VACCINE TRIALS
The development and evaluation of malaria
vaccines is an excellent example of the need for
multidisciplinary research. Vaccine development
begins with basic immunology and molecular
biology but, to move beyond the laboratory, the
input of clinicians, epidemiologists and statisticians
is essential and the involvement of policy makers
and industry speeds the process greatly. Most
malaria vaccine trials that have been conducted to
date have necessarily involved collaboration
between several research institutes, each with its
own skills. The particular skills available at LSHTM
include design and evaluation of clinical trials in
general and vaccine trials in particular. Staff at
LSHTM have been intimately involved in the design
and monitoring of trials of the SPf66 vaccine in
Tanzania and in The Gambia. More recently, Tom
Doherty and Brian Greenwood have taken part in
the first field trial of the RTS,S/SBAS2 vaccine
developed by Smith Kline Beecham Biologicals in
collaboration with the Walter Reed Army Institute
of Research and based upon the circumsporozoite
protein of P. falciparum (Stoute et al. 1997); a pilot
study has shown that the vaccine is both safe and
immunogenic (Doherty et al. 1999). The trial, funded
by the European Union and co-ordinated by the
Medical Research Council Laboratories in The
Gambia, was a double blind, placebo-controlled trial
in which 306 men (aged 18 to 45 years) were
vaccinated, cleared of any existing malaria
infections and monitored for reappearance of blood
stage parasites during the following malaria
transmission season. The results of this trial are
due to be published shortly.
As immunity was believed to be at least partially
cell-mediated, and as polymorphisms in T cell
epitopes of the CS gene are known to facilitate im-
mune evasion (as discussed above), breakthrough
infections were typed at LSHTM for polymorphisms
in the regions of the gene encoding immunodominant
T cell epitopes (Th2R/Th3R). Ali Alloueche used
sequence-specific oligonucleotide probes to detect
16 different alleles of the CS gene in PCR-amplified
parasite DNA obtained from vaccinated and control
individuals (Alloueche et al. 2000). There was no
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significant difference in allele frequencies between
the two groups and no evidence that the vaccine
was selecting for breakthrough infections of a dif-
ferent genotype. If the vaccine is ultimately shown
to protect against infection and disease in children,
and introduced as a routine vaccination in endemic
countries, periodic monitoring will be needed to en-
sure that vaccine resistant parasites are not building
up in the population.
IMPLEMENTATION STRATEGIES FOR INSECTICIDE
TREATED BED NETS
The use of insecticide treated bed nets (ITBNs)
for prevention of contact between humans and
mosquitoes is one of the most successful new ap-
proaches for malaria control in Africa; almost all
trials have shown significant reductions in child
mortality and a recent meta-analysis confirms these
findings (Lengeler 2000). Although of limited use
in some parts of the world, where the predominant
vector species bite outdoors and in the evening or
early morning, the argument for widespread intro-
duction of ITBNs in sub-Saharan Africa is over-
whelming. The major issue now is how to achieve
this. Locally produced nets can now be bought in
Tanzania, for example, for as little as $4.00 and if
well cared for may last several years. Insecticide
treatment of the nets can be done at the household
or community level but needs to be repeated at
regular intervals; the insecticide itself (a pyrethroid)
is inexpensive ($0.30 per net per year) and can be
prepackaged in single net doses (Lines & Zaim
2000). Cost-effectiveness analysis (see below) in-
dicates that provision of insecticide through na-
tional health programmes is a realistic expectation,
although there are unresolved issues regarding
monitoring of uptake and effectiveness of dipping
procedures. However, the main problem at the mo-
ment is how to achieve high levels of net use.
Social scientists and entomologists at LSHTM
have been working together to resolve this problem
(Lines 1996). Chris Curtis and colleagues are
investigating the “mass effect” of ITBNs – i.e. are
high levels of ITBN coverage within a village
required to significantly reduce morbidity and
mortality from malaria, or will an individual sleeping
under an ITBN be protected even if his neighbours
are not using ITBNs? (Maxwell et al. 1999). The
answer to this question is important as it will inform
strategies for net distribution. If high levels of
compliance are required at the individual level to
afford protection at the population level, net
distribution should be regarded as a public health
measure (like vaccination) and should be managed
as such. Alternatively, if individual nets protect
individual users, net use can be viewed as a personal
choice (like contraceptive use) – in which case their
uptake could be promoted through health educa-
tion initiatives but their provision could be man-
aged through the commercial sector (Schellenberg
et al. 1999). Jo Lines, Kara Hanson and Caroline
Jones are studying the effects of these two differ-
ent approaches to ITBN distribution in Tanzania
and also trying to answer the vexed questions of
whether social marketing is an effective means of
distributing a (relatively) expensive health product
(i.e. a bednet) and whether undercutting the
commercial market for nets by government subsidy
or non-governmental agency donation programmes
will lead to loss of sustainability.
MALARIA AND ECONOMICS AT LSHTM
One of the most effective means of getting new
malaria control methods adopted and put into
practice is to convince funding agencies (both
governments and non-governmental organisations)
that the interventions are highly cost-effective.
Understanding the economics of malaria and malaria
control is a central part of this process. The malaria
economics group at LSHTM has been leading the
way in this type of analysis.
In a study that estimated the cost per disabil-
ity-adjusted life years (DALYs) averted by various
malaria interventions, Anne Mills, Catherine
Goodman and Paul Coleman found that in very low
income countries with high malaria transmission,
insecticide-treated bed nets, residual spraying and
chemoprophylaxis for children, all cost less than
US$100 per DALY and thus, on the basis of inter-
national guidelines (WHO 1996), can be consid-
ered extremely cost effective interventions
(Goodman et al. 1999). Importantly, the study
showed that it was more cost-effective to prevent
malaria in pregnancy through intermittent treatment
with SP than with weekly chloroquine chemopro-
phylaxis. When expressed as a proportion of the
annual health budget of a very low income coun-
try, residual spraying turned out to be the most
expensive option (accounting for 55% of annual
health expenditure for two rounds of spraying per
year) whereas provision of insecticide for people
to dip their own bed nets cost less than 3% of the
health budget, and intermittent treatment of preg-
nant women with SP and a variety of measures to
improve case man-agement each cost less than 1%
(Goodman et al. 2000). Cost-effectiveness analysis
is now being applied to the problem of changing
the first-line drug for treatment of malaria cases and
to the use of combinations of two or more drugs in
an attempt to increase drug efficacy and slow the
spread of drug resistance. Calculations of this type
are essential for rational and effective use of lim-
ited health resources in low-income countries where
malaria places a major burden on health facilities.
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THE FUTURE
Reducing mortality and morbidity from malaria is
a major challenge for the 21st century. New
technologies are rapidly being taken up by malaria
researchers and are being successfully applied to
research questions – the biotechnology revolution
(Gardner 1999) and geographic information systems
(GIS) are two very notable examples. In the latter
case, GIS mapping is revealing a hitherto unrealized
complexity of malaria transmission and morbidity at
the microepidemiological level (Snow et al. 1999) and
its combination with meteorological data is giving
us a much better picture of the time-space co-
ordinates of malaria outbreaks and their relationship
to changing climatic and environmental conditions
(Bouma et al. 1997, Craig et al. 1999). This has major
implications for long term forecasting of malaria epi-
demics and we look forward to the time when malaria
control personnel in endemic regions can access the
latest malaria forecasts for their area from their desk
top computers via the world wide web; this should
be a reality within five years and should allow ma-
laria outbreaks to be predicted and either prevented,
interrupted (by vector control or use of transmis-
sion-blocking drugs or vaccines) or managed
(through provision of sufficient and appropriate
drugs to hospitals and health centres).
However, as has been all too obvious in the last
one hundred years, the development of new tools
is not – on its own – a guarantee of improvements
on the ground. Continual communication between
researchers, practitioners and policy makers is
essential to make sure that the right tools are applied
in the right place and that their use is acceptable,
affordable and sustainable. Encouraging the
development of multidisciplinary research and
control teams is one way to promote such com-
munication.
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